Results 221 to 230 of about 106,261 (297)

Effect of a Single Oral Dose of Dexamphetamine or Zolpidem on Attention and Reaction Time in Healthy Men

Fundamental &Clinical Pharmacology, Volume 40, Issue 3, May 2026.
ABSTRACT Psychotropic medicines are known to impair cognitive function acutely, but the specific effects of individual substances remain underexplored. This study investigates the effects of dexamphetamine and zolpidem on cognitive performance to quantify the potential risk of intake and their pharmacokinetic and pharmacodynamic relationship.
Veronika Pfoser‐Poschacher, Michael Wolf, Michaela Bayerle‐Eder, Teresa Wimmer, Daniela Boryshchuk, Christopher Gerner, Michael Wolzt   +6 more
wiley   +1 more source

Residual Intravenous Contrast Mimicking a Ureteral Stent on Noncontrast Computed Tomography in a Patient With Ureterolithiasis. [PDF]

Cureus
Beyer BR, Haq A.
europepmc   +1 more source

Fulminant type 1 diabetes with high‐titer anti‐glutamic acid decarboxylase antibodies: Likely rapid progression from stage 2 to 3

Journal of Diabetes Investigation, Volume 17, Issue 5, Page 892-896, May 2026.
Abstract A 61‐year‐old man visited our hospital with a sudden onset of polydipsia and polyuria occurring 5 days prior, accompanied by a 5‐kg weight loss. A month prior, his glycated hemoglobin level was 6.2%. Precisely 8 days before the first visit, he had a fever, and hyperglycemic symptoms began shortly thereafter.
Megumi Sato, Junnosuke Miura, Hikaru Oyatsu, Yuka Yoshida, Shota Mochizuki, Michio Otsuki, Tomoko Nakagami   +6 more
wiley   +1 more source

Drug Testing High School and Junior High School Students After Veronia School District 47J v. Acton: Proposed Guidelines for School Districts [PDF]

, 2011
Massmann, Andrew P.
core   +1 more source

Safety and efficacy of nemolizumab for atopic dermatitis up to 2 years in open‐label extension study

Journal of the European Academy of Dermatology and Venereology, Volume 40, Issue 5, Page 841-855, May 2026.
This study evaluated long‐term safety and efficacy in patients with moderate‐to‐severe atopic dermatitis. Patients with and without previous nemolizumab experience received nemolizumab 30 mg Q4W plus TCS/TCI. Nemolizumab was well‐tolerated through 104 weeks with clinically meaningful improvements in disease signs and symptoms.
Matthias Augustin, Marie Tauber, Robert Sidbury, Jonathan I. Silverberg, Kim A. Papp, Diamant Thaçi, Marjolein S. De Bruin‐Weller, Adam Reich, Ketty Peris, Kirk Barber, Ryszard Galus, Andrzej Kaszuba, Matthew Zirwas, Walter K. Nahm, Gretel Trullenque, Laura Maintz, Sady Alpizar, Sang Wook Son, Vivian Laquer, Linda Stein Gold, Soo Yeon Cheong, Anna Ryzhkova, Agnes Drahos, Liliana Ulianov, Christophe Piketty   +24 more
wiley   +1 more source

From glucosuria to dialysis: a case report of osmotic nephropathy due to an SGLT2 inhibitor. [PDF]

BMC Nephrol
Castellanos-de la Hoz J, Molano-Triviño A, González-García YF, Espinosa Saltaren LM, Zúñiga-Rodríguez E.   +4 more
europepmc   +1 more source

Isolated Kidney Transplant in Primary Hyperoxaluria‐1 Enabled by Small Interfering RNA (siRNA) Therapy. Is It Time for Change? Case Report and Review of the Literature

Pediatric Transplantation, Volume 30, Issue 5, May 2026.
ABSTRACT Background Primary hyperoxaluria type 1 (PH1) is a rare genetic disorder characterized by excessive oxalate production that leads to nephrocalcinosis or nephrolithiasis and progressive kidney failure, associated with systemic oxalosis that is not reversed by dialysis. Pharmacological treatment is limited.
Shameer M. Habeeb, Eva Simkova, Samhar Al‐Akash, Hazem S. Awad, Haneen Yamin, Loai A. Eid, Watfa S. Aldhaheri, Waldo Concepcion, Martin Bitzan   +8 more
wiley   +1 more source

Clinical factors and diagnoses associated with inappropriate urine culture ordering in primary care. [PDF]

Infect Control Hosp Epidemiol
Valentine-King M, Trautner BW, Hansen MA, Zoorob R, Danek LCK, Muldrew K, Hudson F, Atmar RL, Grigoryan L.   +8 more
europepmc   +1 more source

Safety evaluation of the food enzyme phospholipase D from the genetically modified Streptomyces violaceoruber strain pPDN

EFSA Journal, Volume 24, Issue 5, May 2026.
Abstract The food enzyme phospholipase D (phosphatidylcholine phosphatidohydrolase; EC 3.1.4.4) is produced with the genetically modified Streptomyces violaceoruber strain pPDN by Nagase ChemteX. The production strain of the food enzyme contains several antimicrobial resistance genes, of which at least one is acquired.
EFSA Panel on Food Enzymes (FEZ), Holger Zorn, José Manuel Barat Baviera, Claudia Bolognesi, Francesco Catania, Gabriele Gadermaier, Ralf Greiner, Baltasar Mayo, Alicja Mortensen, Yrjö Henrik Roos, Marize L. M. Solano, Henk Van Loveren, Laurence Vernis, Andrew Chesson, Jaime Aguilera, Magdalena Andryszkiewicz, Daniele Cavanna, Natalia Kovalkovicova, Yi Liu, Giulio di Piazza, Rita Ferreira de Sousa   +20 more
wiley   +1 more source

The U-POCUS protocol: urinalysis and point-of-care ultrasound to exclude symptomatic ureterolithiasis in emergency department patients. [PDF]

CJEM
Tripod M, Mendez K, Berger M, Shaffer C, Yeung T, Costantino TG, Peterson S, Gibbons RC.   +7 more
europepmc   +1 more source